<DOC>
	<DOCNO>NCT00424632</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose recommend phase 2 dose PF-03814735 administer orally single agent patient advance solid tumor .</brief_summary>
	<brief_title>Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Metastatic solid tumor resistant standard therapy standard therapy available Adequate bone marrow , liver kidney function Brain metastases symptomatic and/or require treatment steroid and/or anticonvulsant , brain metastasis treat within 3 month prior study start Myocardial infarction , severe/unstable angina , symptomatic congestive heart failure , cerebrovascular accident previous 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>